Letermovir: First Global Approval
- PMID: 29288370
- DOI: 10.1007/s40265-017-0860-8
Letermovir: First Global Approval
Abstract
Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.
Similar articles
-
Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.Drugs Today (Barc). 2018 Jun;54(6):361-368. doi: 10.1358/dot.2018.54.6.2833982. Drugs Today (Barc). 2018. PMID: 29998227 Review.
-
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6. N Engl J Med. 2017. PMID: 29211658 Clinical Trial.
-
Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.Future Microbiol. 2019 Feb;14:175-184. doi: 10.2217/fmb-2018-0250. Epub 2019 Jan 15. Future Microbiol. 2019. PMID: 30644320
-
Letermovir for the management of cytomegalovirus infection.Expert Opin Investig Drugs. 2017 Feb;26(2):235-241. doi: 10.1080/13543784.2017.1274733. Epub 2016 Dec 28. Expert Opin Investig Drugs. 2017. PMID: 27998189 Review.
-
Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.Clin Drug Investig. 2024 Jul;44(7):527-540. doi: 10.1007/s40261-024-01376-w. Epub 2024 Jun 27. Clin Drug Investig. 2024. PMID: 38935253 Free PMC article.
Cited by
-
HCMV Antivirals and Strategies to Target the Latent Reservoir.Viruses. 2021 May 1;13(5):817. doi: 10.3390/v13050817. Viruses. 2021. PMID: 34062863 Free PMC article. Review.
-
Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.Ann Hematol. 2024 Feb;103(2):609-621. doi: 10.1007/s00277-023-05542-6. Epub 2023 Nov 14. Ann Hematol. 2024. PMID: 37957371
-
Releasing the concept of HLA-allele specific peptide anchors in viral infections: A non-canonical naturally presented human cytomegalovirus-derived HLA-A*24:02 restricted peptide drives exquisite immunogenicity.HLA. 2019 Jul;94(1):25-38. doi: 10.1111/tan.13537. Epub 2019 Apr 14. HLA. 2019. PMID: 30912293 Free PMC article.
-
Synthesis of New Imidazopyridine Nucleoside Derivatives Designed as Maribavir Analogues.Molecules. 2020 Oct 3;25(19):4531. doi: 10.3390/molecules25194531. Molecules. 2020. PMID: 33022923 Free PMC article.
-
The World of Antiherpetic Vaccines and Drugs, 2022.Viruses. 2022 Apr 20;14(5):850. doi: 10.3390/v14050850. Viruses. 2022. PMID: 35632592 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
